<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01619644</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2011/20</org_study_id>
    <nct_id>NCT01619644</nct_id>
  </id_info>
  <brief_title>Rubinstein-Taybi Syndrome: Functional Imaging and Therapeutic Trial</brief_title>
  <acronym>RUBIVAL</acronym>
  <official_title>Rubinstein-Taybi Syndrome: Functional Imaging and Therapeutic Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondation Syndrome de Rubinstein-Taybi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An exploratory phase 2 therapeutic trial in children from 6 to 21, RTS carriers, randomized&#xD;
      to be treated either with sodium valproate with the usual pediatric dosage (30 mg/kg/j), or&#xD;
      by placebo for one year.&#xD;
&#xD;
      The investigator would like to include children because they could best profit from it due to&#xD;
      their neuronal plasticity as CBP and EP300 take effect through neuronal and synaptic&#xD;
      plasticity.&#xD;
&#xD;
      The therapeutic effect of sodium valproate in RTS patients will be assessed thanks to a&#xD;
      clinical approach (learning and memory neuropsychological evaluation, fine motor skills&#xD;
      assessment by pointing), to a biological approach (histone acetylation functional tests), and&#xD;
      to imaging (morphological and functional MRI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Such a multidisciplinary approach has never been presented for this syndrome; it should&#xD;
      enable us identifying specific cognitive and motor deficits and their association thanks to&#xD;
      imaging markers. Assessing the various aspects of motor skills, i.e. primary (movements,&#xD;
      standing at ease position, immobility) and complex motor skills (actions and behaviours,&#xD;
      motor aspects of feelings and language expressions) is an integral part of the clinical&#xD;
      examination in psychiatrics.&#xD;
&#xD;
      The main interest of a functional capacity analysis is to be used as an index allowing the&#xD;
      assessment of the nervous system's global capacities and the study of the connections between&#xD;
      cognitive functions and motor skills Main objective: Evaluate long term memory with subtest&#xD;
      &quot;point location&quot; - CMS and &quot;image recognition&quot; RBMT A patient is said to be responder if&#xD;
      after one year his or her test result increase for one point at least one of the two tests :&#xD;
      a increase of one point to &quot;point location&quot; or &quot;image recognition&quot;.&#xD;
&#xD;
      Double-blind phase 2 clinical trial, designed as a one-step Fleming design but with a control&#xD;
      group. Rubival is a two-parallel group randomized trial:&#xD;
&#xD;
        -  a placebo group of 20 patients&#xD;
&#xD;
        -  a group of 40 patients taking sodium valproate (HDAC inhibitor) with an oral dosage of&#xD;
           30 mg/kg/jour&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Memory tests (assessing memory learning)</measure>
    <time_frame>1 year</time_frame>
    <description>The main outcome measure was to evaluate long term memory with two subtests :&#xD;
point location, subtest of CMS (children memory scale). The score ranges from 0 to 6&#xD;
image recognition, subtest of RBMT (Rivermead Behavioural Memory Test). The score range from 0 to 10. One point for each image recognized A patient is said to be responder if after one year of treatment , his or her test result increase for one point at least one of the two tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Special brain imaging profile and motor skills (posturology and motor coordination in a visio-manual pointing task)</measure>
    <time_frame>1 year</time_frame>
    <description>For motor skills, the profile was based on 3 tasks : posturology, motor coordination in a visuo-manual pointing task and in mobile interception task..&#xD;
For brain imaging, a variety of outcome measures will be used for example, brain volume, anisotropy fraction, diffusion coefficient for structural magnetic imaging and the signal intensity for functional Magnetic Resonance Imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive and developmental profile</measure>
    <time_frame>1 year</time_frame>
    <description>Based on the results of several battery test and evaluation scale, VABS II (Vineland Adaptative Behaviour Scale II), Leiter R, EVIP, ECOSSE, NEPSY : fluency verbal sutest, CMS : 2 subtests, RBMT : 1 subtest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histone acetylation profile</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global acetylation level</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acetylation level of selected gene</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of selected gene expression</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Rubinstein-Taybi Syndrome</condition>
  <arm_group>
    <arm_group_label>Sodium Valproate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group of 40 patients receiving one year of sodium valproate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group of 20 patients receiving one year of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium valproate</intervention_name>
    <description>sodium valproate (HDAC inhibitor) with an oral dosage of 30 mg/kg/jour</description>
    <arm_group_label>Sodium Valproate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo with an oral dosage of 30 mg/kg/jour</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children over 6 and under 21&#xD;
&#xD;
          -  RTS confirmed by a genetic study with a CBP gene or EP300 gene mutation&#xD;
&#xD;
          -  Sufficient cognitive capacities for neuropsychological evaluation&#xD;
&#xD;
          -  Free and informed consent of the parents or guardians&#xD;
&#xD;
          -  Children affiliated to or benefiting of the French social welfare system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to sodium valproate&#xD;
&#xD;
          -  Women of reproductive age without effective contraception means&#xD;
&#xD;
          -  Case history of sodium valproate treatment&#xD;
&#xD;
          -  Monotherapy treatment for epilepsy with Lamictal with a dosage superior to 5 mg/kg/j&#xD;
&#xD;
          -  Family history of severe hepatitis including drug&#xD;
&#xD;
          -  Acute or chronic hepatitis&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier LACOMBE, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Bordeaux, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul PEREZ, PH</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Bordeaux, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Bordeaux, France</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>June 12, 2012</study_first_submitted>
  <study_first_submitted_qc>June 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2012</study_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RTS</keyword>
  <keyword>Rubinstein Taybi</keyword>
  <keyword>explorative phase 2</keyword>
  <keyword>clinical approach</keyword>
  <keyword>biological approach</keyword>
  <keyword>motor skills</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hand Deformities, Congenital</mesh_term>
    <mesh_term>Osteochondrodysplasias</mesh_term>
    <mesh_term>Craniofacial Abnormalities</mesh_term>
    <mesh_term>Rubinstein-Taybi Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

